Muromonab

Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients[1][2][3][4][5].

Product Specifications

CAS Number

[140608-64-6]

Product Name Alternative

Muromanab-CD3

UNSPSC

12352203

Target

CD3; IFNAR; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/muromonab.html

Purity

98.74

Solubility

10 mM in DMSO

Smiles

[Muromonab]

Molecular Weight

(146.34 kDa)

References & Citations

[1]P A Todd, et al. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37 (6) :871-99.|[2]Lahdou I, et al. Role of human corneal endothelial cells in T-cell-mediated alloimmune attack in vitro. Invest Ophthalmol Vis Sci. 2014 Mar 3;55 (3) :1213-21.|[3]Yan H, et al. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Transl Res. 2019 Aug;210:43-56.|[4]Ménoret S, et al. Efficient generation of human immune system rats using human CD34+ cells. Stem Cell Reports. 2024 Sep 10;19 (9) :1255-1263.|[5]OKT 3. Sciencedirect.|[6]Deters M, et al. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. Phytomedicine. 2013 Jan 15;20 (2) :120-3.